Log in
NASDAQ:IMMU

Immunomedics Stock Forecast, Price & News

$85.03
-0.22 (-0.26 %)
(As of 09/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$84.84
Now: $85.03
$85.33
50-Day Range
$40.00
MA: $55.52
$85.53
52-Week Range
$8.80
Now: $85.03
$86.91
Volume5.67 million shs
Average Volume3.94 million shs
Market Capitalization$19.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.42
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Read More
Immunomedics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IMMU
CUSIP45290710
Phone973-605-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Price / Sales67,773.01
Book Value$1.38 per share

Profitability

Net Income$-357,190,000.00

Miscellaneous

Employees346
Market Cap$19.65 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$85.03
-0.22 (-0.26 %)
(As of 09/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

How has Immunomedics' stock price been impacted by COVID-19?

Immunomedics' stock was trading at $13.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMMU shares have increased by 535.5% and is now trading at $85.03.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Immunomedics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Immunomedics
.

When is Immunomedics' next earnings date?

Immunomedics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Immunomedics
.

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) issued its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.39. The biopharmaceutical company earned $20.07 million during the quarter, compared to the consensus estimate of $24.81 million.
View Immunomedics' earnings history
.

What price target have analysts set for IMMU?

11 brokerages have issued 12 month price targets for Immunomedics' shares. Their forecasts range from $22.00 to $88.00. On average, they anticipate Immunomedics' stock price to reach $49.55 in the next twelve months. This suggests that the stock has a possible downside of 41.7%.
View analysts' price targets for Immunomedics
.

Has Immunomedics been receiving favorable news coverage?

News coverage about IMMU stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Immunomedics earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
View the latest news about Immunomedics
.

Who are some of Immunomedics' key competitors?

What other stocks do shareholders of Immunomedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Celgene (CELG), Micron Technology (MU), NVIDIA (NVDA), Seattle Genetics (SGEN), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Exelixis (EXEL) and ImmunoGen (IMGN).

Who are Immunomedics' key executives?

Immunomedics' management team includes the following people:
  • Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)
  • Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)
  • Mr. Scott A. Canute MBA, Exec. Director (Age 58)
  • Mr. Brendan Delaney, Chief Commercial Officer (Age 44)
  • Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $85.03.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $19.65 billion and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-357,190,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Immunomedics employs 346 workers across the globe.

What is Immunomedics' official website?

The official website for Immunomedics is www.immunomedics.com.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.